title: Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
abstract: Imatinib mesylate is the first molecule of targeted therapy in chronic myelogenous leukaemia inhibiting constitutively activated BCR-ABL kinase. There are no long-term follow-up studies of large sample sizes to assess the toxicity of the use of imatinib mesylate over 10 years. Several cases of hepatotoxicity, including fatal liver failure, have been associated with the long-term use of imatinib mesylate. We report here on a patient who experienced immediate dominant cholestatic damage of the liver and mild hepatocyte damage during imatinib mesylate therapy. This differs from most reports showing dominantly acute hepatitis with necrosis associated with the use of imatinib mesylate.
authors.affiliation: Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Ewha Womans University, Seoul, Korea.
authors.forename: Jee Hyun
authors.initials: JH
authors.lastname: Kong
authors.forename: Seung-Hyun
authors.initials: SH
authors.lastname: Yoo
authors.forename: Kyoung Eun
authors.initials: KE
authors.lastname: Lee
authors.forename: Seung Hyun
authors.initials: SH
authors.lastname: Nam
authors.forename: Jung Mi
authors.initials: JM
authors.lastname: Kwon
authors.forename: Sang Min
authors.initials: SM
authors.lastname: Lee
authors.forename: Hye Jung
authors.initials: HJ
authors.lastname: Chang
authors.forename: Moon Young
authors.initials: MY
authors.lastname: Choi
authors.forename: Min Sun
authors.initials: MS
authors.lastname: Cho
authors.forename: Yeung-Chul
authors.initials: YC
authors.lastname: Mun
authors.forename: Eunmi
authors.initials: E
authors.lastname: Nam
authors.forename: Soon Nam
authors.initials: SN
authors.lastname: Lee
authors.forename: Chu-Myong
authors.initials: CM
authors.lastname: Seong
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D001652:Bile Ducts / Q000473:pathology; D001752:Blast Crisis / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced*; D003561:Cytarabine / Q000008:administration & dosage; D003875:Drug Eruptions / Q000209:etiology; D022781:Hepatocytes / Q000473:pathology; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D003561:Cytarabine; D000068877:Imatinib Mesylate; D015255:Idarubicin